

Characterisation of sensor accuracy performance for Continuous Glucose Monitoring (CGM) systems

Submission date 19/05/2025	Recruitment status Recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 28/05/2025	Overall study status Ongoing	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 27/05/2025	Condition category Nutritional, Metabolic, Endocrine	<input type="checkbox"/> Individual participant data
		<input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aim

The purpose of this study is to characterize the accuracy performance of different CE-marked CGM.

Who can participate?

Anyone aged 18 years or older with type 1 or type 2 diabetes.

What does the study involve?

During this study adult subjects with Type 1 or Type 2 diabetes will wear up to three sensors for a period of up to 31 days depending on each sensor's indications.

During the period of sensor wear participants will go about their normal daily activities while wearing the sensors. Participants will be asked to perform at least four Blood Glucose fingerprick tests per day (before meals and bedtime).

What are the possible benefits and risks of participating?

The data collected in this study could contribute to increase the understanding of available devices to monitor glucose for people living with diabetes as well as giving more people the opportunity to experience the use of CGM devices.

There are small risks associated with use of any sensor device that punctures and adheres to the skin, these include erythema, oedema, rash, itching, bruising, pain, bleeding, induration and infection.

The study participants will perform blood glucose tests. Risks are small but could include pain, bruising, local infection and fainting caused by the lancet used to obtain a blood sample.

Where is the study run from?

The study is run by 2 sites in UK, MAC Clinical Research Glasgow and MAC Clinical Research Barnsley.

When is the study starting and how long is it expected to run for?

June 2024 to April 2025.

Who is funding the study?
The study is funded by Abbott Diabetes Care Ltd (UK).

Who is the main contact?
Dr Pamela Reid, pamelareid@abbott.com

Contact information

Type(s)
Public, Scientific

Contact name
Dr Pamela Reid

Contact details
Range Road
Witney
United Kingdom
OX29 0YL
+44 1993 863024
pamelareid@abbott.com

Type(s)
Principal investigator

Contact name
Dr Ivelin Trifonov

Contact details
Phoenix House, Maple Road
Tankersley
United Kingdom
S75 3DL
+44 (0) 1226 356940
ivelintrifonov@macplc.com

Additional identifiers

Clinical Trials Information System (CTIS)
Nil known

Integrated Research Application System (IRAS)
355902

Protocol serial number
Nil known

Study information

Scientific Title

Characterisation of sensor accuracy performance for CGM systems

Study objectives

The study aims to characterise the performance and collect safety data of different Continuous Glucose Monitoring (CGM) systems in people living with diabetes. Results will be characterised in terms of point accuracy of each CGM system with respect to capillary fingerstick blood glucose values.

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 16/04/2025, Yorkshire & The Humber - Leeds West Research Ethics Committee (NHSBT Newcastle Blood Donor Centre Holland Drive, Newcastle upon Tyne, NE2 4NQ, United Kingdom; +44 207 972 25 04; leedswest.rec@hra.nhs.uk), ref: 25/YH/0073

Study design

Post-market single arm prospective study

Primary study design

Intentional

Study type(s)

Other

Health condition(s) or problem(s) studied

Diabetes mellitus

Interventions

Each study arm will involve the use of CE-marked Continuous Glucose Monitoring (CGM) systems. Adults with Type 1 or Type 2 diabetes will wear between one and three sensors for a period of up to 31 days depending on each sensor's wear indications. During the period of sensor wear participants will go about their daily activities and will be asked to perform at least four Blood Glucose (BG) fingerprick tests per day. At Visit 2, sensors are removed, and adverse events are documented, if any.

Intervention Type

Device

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

CE-marked Continuous Glucose Monitoring (CGM) Systems

Primary outcome(s)

The proportion of system readings that are within $\pm 20\%$ for glucose levels ≥ 70 mg/dL and within ± 20 mg/dL for glucose levels < 70 mg/dL compared to capillary fingerstick blood glucose (BG) values, over the duration of sensor wear

Key secondary outcome(s)

Safety outcomes (AEs/ DIs) will be recorded, over the duration of sensor wear

Completion date

13/04/2035

Eligibility

Key inclusion criteria

1. Aged at least 18 years old.
2. Have type 1 or type 2 diabetes.
3. Is willing to provide a minimum of 4 and no more than 12 capillary fingerprick blood samples for each day of sensor wear.
4. Is able to read and understand English.
5. In the investigator's opinion, the participant is willing to wear the sensor(s), to follow the instructions provided to him/her by the study site and perform all study tasks as specified by the protocol.
6. Agrees to continue using their current method of glucose monitoring for duration of study.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. Has participated in the same study event.
2. Is a member of the study staff.
3. Is pregnant, planning to become pregnant within the study event duration, or becomes pregnant during the study.
4. Has known (or suspected) allergy to medical grade adhesive at enrolment.
5. Has a skin abnormality at the application sites.
6. Is currently participating in another clinical study that could affect their glucose management.
7. Has a known concomitant medical condition which, in the opinion of the investigator, could present a risk to the safety or welfare of the participant or study staff.
8. Has a pacemaker or any other neurostimulators.
9. Is unsuitable for participation due to any other cause as determined by the investigator.

Date of first enrolment

19/05/2025

Date of final enrolment

01/04/2035

Locations**Countries of recruitment**

United Kingdom

England

Scotland

Study participating centre**MAC Clinical Research Glasgow**

Fleming Pavilion, Todd Campus, West of Scotland Science Park

Glasgow

United Kingdom

G20 0XA

Study participating centre**MAC Clinical Research Barnsley**

Phoenix House

Maple Road

Barnsley

United Kingdom

S75 3DL

Sponsor information**Organisation**

Abbott Diabetes Care Ltd.

Funder(s)**Funder type**

Industry

Funder Name

Abbott Diabetes Care Ltd

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are not expected to be made available due to the fact the individual participant data is already available to participant and HCP on study completion.

IPD sharing plan summary

Not expected to be made available